Medical Oncologist
Reading your oncology report
Understanding PFS, OS and — Median Survival
When a report or a clinical trial result mentions median survival, PFS or OS, the numbers can feel like a verdict. They are not. Each term describes how a group of patients in a study behaved — not what will happen to you.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- A group statistic, not a forecast — Median survival describes a population in a past trial. It cannot tell you where you personally will land.
- PFS and OS measure different things — PFS tracks how long disease stays controlled. OS tracks how long someone lives. Neither is the complete picture on its own.
- Half always lived longer — The median is the midpoint. For every patient below it, there is one above it — often considerably above it.
- Your biology is not averaged — Your tumour markers, fitness, and treatment response are not captured in any population figure from a trial.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Median survival means half the people in a clinical trial lived longer than that figure, and half did not. It describes the group studied, not a forecast for you. Your individual outcome depends on your specific cancer biology, treatment response, and factors your oncologist can explain — not a number from a past trial.
What do PFS, OS and median survival actually mean?
- PFS — Progression-Free Survival
- The length of time during and after treatment that the cancer does not grow or spread. It measures how well treatment is controlling the disease, not whether the cancer has gone away permanently.
- OS — Overall Survival
- The length of time from a set point — usually the start of treatment — that a patient is still alive. It is the most direct measure of whether a treatment extends life.
- Median survival
- The midpoint of a group's survival times in a trial. Half the patients lived longer than this figure; half did not. It describes where the group sat — it says nothing about which half you will be in.
- ORR — Overall Response Rate
- The proportion of patients in a trial whose tumour shrank by a defined amount. A treatment can have a strong response rate and a modest median survival, or the reverse — the two measure different things.
How are PFS and OS different from each other?
| Feature | PFS | OS |
|---|---|---|
| What it measures | Disease not growing or spreading | Patient being alive |
| When the clock starts | Start of treatment | Diagnosis or start of treatment |
| What a good result suggests | Treatment is controlling the cancer | Treatment may be extending life |
| Its main limitation | Does not capture what happens after disease eventually returns | Can be influenced by treatments given after the trial drug has stopped |
| When it is most useful | Comparing how quickly two treatments control disease | Establishing whether one treatment helps people live longer |
Why does the median not predict what will happen to me?
The median is a midpoint, not a ceiling. For every patient in a trial who lived a shorter time than the median, there was one who lived longer — sometimes much longer. The figure tells you where the group sat; it does not tell you where you will sit.
Clinical trial populations are not identical to you. People enrolled had specific eligibility criteria and a mix of tumour characteristics within the same broad diagnosis. Your tumour biology, the treatments available to you now, and your response to them are yours specifically.
The data is also often several years old. Treatments approved since the trial was run may change outcomes in ways the original median cannot reflect.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
What should you ask when a survival figure comes up?
- Ask when the trial was conducted — figures from five or more years ago may not reflect current treatment options.
- Ask how similar the trial population was to you in terms of stage, biomarker profile, and prior treatment.
- Ask what the outcomes were for patients who responded well — that subgroup is often more relevant than the overall median.
- Ask whether more recent follow-up data from the same trial exists — results are often updated over time.
- Write down the specific figure and where it came from, so you can return to the same question at future appointments.
Did you know?
S
u
r
v
i
v
a
l
c
u
r
v
e
s
i
n
c
a
n
c
e
r
t
r
i
a
l
s
a
l
m
o
s
t
a
l
w
a
y
s
s
h
o
w
a
g
r
o
u
p
o
f
p
a
t
i
e
n
t
s
l
i
v
i
n
g
w
e
l
l
b
e
y
o
n
d
t
h
e
r
e
p
o
r
t
e
d
m
e
d
i
a
n
.
T
h
i
s
'
t
a
i
l
o
f
t
h
e
c
u
r
v
e
'
r
e
p
r
e
s
e
n
t
s
r
e
a
l
p
e
o
p
l
e
w
h
o
s
e
o
u
t
c
o
m
e
s
t
h
e
m
e
d
i
a
n
a
l
o
n
e
c
a
n
n
o
t
d
e
s
c
r
i
b
e
—
y
e
t
i
t
i
s
r
a
r
e
l
y
t
h
e
n
u
m
b
e
r
t
h
a
t
a
p
p
e
a
r
s
i
n
h
e
a
d
l
i
n
e
s
o
r
s
u
m
m
a
r
i
e
s
.
Source: ESMO and ASCO guidelines on reporting clinical trial survival outcomes
What else do I need to know about these survival numbers?
Does a low median survival mean my treatment is not working?
No. Median survival is a property of a past clinical trial, not a measure of how your treatment is going today. Whether your treatment is working is answered by your own scans, markers and symptoms — none of which are captured in a trial figure. Your oncologist assesses your response through results specific to you, and that is the conversation worth having rather than comparing your experience to a published number.
What if I have already lived beyond the median?
It means you are in the half of patients who lived longer than the midpoint in the study being referenced. The median is a statistical boundary, not a line beyond which outcomes change. Many patients continue well beyond it. Passing the median is not a cause for concern — it simply confirms that the most common outcome in that study applies to the other half, not to you.
Does a better PFS always mean I will live longer?
Not automatically, and this is an active area of research in oncology. Some treatments control disease effectively for a period without extending overall life expectancy. Others improve PFS in ways that do translate into longer survival. The relationship between the two depends on the cancer type and the drug. Your oncologist can explain what the evidence shows for your specific treatment — the answer is not the same across all cancers.
What is disease-free survival — is it different from PFS?
Disease-free survival is used mainly after surgery or treatment intended to remove all visible cancer. It measures the length of time the patient lives without the cancer returning. PFS, by contrast, is used when some disease may still be present and is being controlled rather than eliminated. The terms are sometimes used interchangeably in reports, so it is worth asking your oncologist which definition applies in your situation.
Why do oncologists use median survival if it is not a personal prediction?
The median is the standard way to compare two treatments in a clinical trial, and it allows doctors and researchers to communicate across studies consistently. The problem arises when it is taken out of context and read as an individual forecast. Your oncologist uses it as one reference point alongside your own results — markers, scans, and clinical assessment — which together give a far more accurate picture of your specific situation than any population figure.
Explore 39 more Monitoring, Resistance & Long-Term Response topics
Monitoring, Scans & Response Assessment
- Are Tumour Markers Reliable on Targeted Therapy?
- Complete Response, Partial Response, Stable Disease: What Each Means
- Do I Need Regular Brain MRIs on Targeted Therapy?
- How Doctors Measure Whether Targeted Therapy Is Working
- How Often Will I Need Scans on Targeted Therapy?
- How to Read a CT or PET Scan Report Without Panicking
- Is 'Stable Disease' Good News or Bad News?
- Scanxiety: How to Get Through the Wait for Scan Results
- Tumour Flare and Pseudoprogression: When Growth Isn't Really Growth
- Understanding PFS, OS and Median Survival Without Losing Hope
- What Happens at a Follow-Up Visit: A Walk-Through
- Which Blood Tests Are Repeated Every Month and Why
- ctDNA Monitoring: Can a Blood Test Predict Progression Early?
Long-Term Response, Stopping & Survivorship
- Am I Still a Cancer Patient? Identity After Long-Term Response
- Bone Health, Heart Health and Late Effects to Monitor
- Can You Ever Stop Targeted Therapy If the Cancer Is Gone?
- Drug Holidays: Are Planned Breaks Safe?
- Follow-Up Schedule After Stopping Targeted Therapy
- How Long Do You Have to Stay on Targeted Therapy?
- Long-Term Effects of Taking a TKI for 5 or 10 Years
- Restarting Treatment After a Break
- Treatment-Free Remission in CML: Who Can Stop Their TKI?
- Your Survivorship Care Plan: What Should Be In It
Resistance, Progression & Next Lines
- Being Told 'There Are No More Options': Is That Really True?
- Brain Metastases on Targeted Therapy: Does Your Drug Reach the Brain?
- Can You Continue the Same Drug After Progression?
- Combination Therapy to Overcome Resistance
- Do You Need Another Biopsy When the Cancer Progresses?
- Histologic Transformation: When Lung Cancer Changes Type
- How to Emotionally Process a Progression Scan
- Leptomeningeal Disease: Symptoms, Diagnosis and Treatment
- Life After ALK Inhibitor Resistance: Sequencing Your Options
- MET Amplification and Other Bypass Resistance Mechanisms
- Oligoprogression: When Only One or Two Spots Grow
- Primary vs Acquired Resistance: Two Very Different Problems
- Should You Change Hospitals After Progression?
- What Happens After Osimertinib Stops Working?
- What Is Sequencing and Why the Order of Drugs Matters
- Why Does Targeted Therapy Stop Working? The Biology of Resistance
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
If the median survival is 12 months, does that mean I have 12 months?
No. The median means that in the clinical trial, half the participants lived longer than that point and half did not. It is a description of that study population — not a personal forecast. Many factors that shape individual outcomes are not captured in a single trial figure: your tumour's specific biology, your response to treatment, your fitness, and the treatments now available to you. Your oncologist's assessment of your own scan results and markers is far more relevant to your situation than any population figure.
What is the difference between PFS and OS?
PFS — progression-free survival — measures how long the cancer stays controlled or stable, meaning it has not grown or spread. OS — overall survival — measures how long the patient lives. A treatment can extend PFS without necessarily extending OS, and the two are reported separately in trials for that reason. Your oncologist will usually explain which endpoint the evidence for your treatment is built on, and what that means for your care.
Why does my oncologist mention response rate separately from survival?
Response rate measures how many patients in a trial had their tumour shrink. Survival measures how long patients lived. A drug can produce a strong response rate — meaning many tumours shrank — without adding substantially to how long patients live, and vice versa. Reporting them separately gives a more complete picture. For you as a patient, response rate tells you whether the drug is active against your cancer type; survival data tells you whether that activity translates into living longer.
Is a higher PFS always better news?
A longer PFS generally means the cancer is being controlled for more time, which matters for quality of life and keeps more options open. However, PFS does not always predict how long someone will live overall — some treatments that improve PFS do not extend overall survival, and this varies by cancer type. Ask your oncologist specifically what the evidence shows for your treatment: whether the PFS benefit seen in trials translated into an OS benefit, and by how much.
Should I avoid reading clinical trial results online?
Reading them is not the problem — reading them without context is. A headline figure such as a median survival is one number from one trial, run in a specific population, often several years ago. If you read a result that worries you, write it down and bring it to your next appointment. Ask your oncologist whether that trial population is comparable to you, and what the current evidence says. Your team can interpret any figure in the context of your own results, which is the only context that matters.
What does it mean if two trials report different median survival figures for the same cancer?
It usually means the two trials enrolled different populations, used different drug combinations, treated disease at different stages, or were conducted at different times. It does not mean one result is wrong. Population figures are sensitive to how a study was designed and who was enrolled. When you see two different numbers, ask your oncologist which trial's population most closely resembles your own situation — that is the figure most relevant to you.